论文部分内容阅读
目的根据前期藿莲香Ⅰ号药效学研究结果,进一步研究该复方的急性毒性和致突变作用,为其进一步应用的安全性提供理论依据。方法应用急性毒性实验、小鼠骨髓嗜多染红细胞微核试验、小鼠骨髓细胞染色体畸变试验和Ames试验检测该组分配伍复方的急性毒性和致突变性。结果急性经口毒性试验:雌性、雄性小鼠经口MTD均大于10g·kg-1,属实际无毒。致突变实验:小鼠骨髓嗜多染红细胞微核试验、小鼠骨髓细胞染色体畸变试验和Ames试验结果均为阴性,显示在本实验条件下,该中药复方未见有致突变性作用。结论中药复方藿莲香Ⅰ号未见有明显的急性毒性和致突变作用,表明该药物安全性良好。
OBJECTIVE To further study the acute toxicity and mutagenicity of this compound according to the pharmacological study results of Agkistrodon I, provide a theoretical basis for its further application. Methods Acute toxicity and mutagenicity were determined by acute toxicity test, micronucleus test of mouse bone marrow polychromatic erythrocytes, chromosome aberration test of mouse bone marrow cells and Ames test. Results Acute oral toxicity test: Female and male mice oral MTD were greater than 10g · kg-1, is actually non-toxic. Mutagenicity experiments: Micronucleus test of mouse bone marrow polychromatic erythrocytes, chromosome aberration test of mouse bone marrow cells and Ames test results were negative, indicating that under the experimental conditions, the Chinese compound has no mutagenic effect. Conclusion There is no obvious acute toxicity and mutagenicity in Chinese herbal compound Ephedra sinica Ⅰ, indicating that the drug is safe.